{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T06:00:23Z","timestamp":1781071223676,"version":"3.54.1"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Interstitial lung disease (ILD) is a potentially fatal adverse effect of anticancer therapy, but comparative ILD reporting associations across antineoplastic agents in sex hormone-sensitive solid tumors (breast, ovarian, and prostate cancers) remain unclear. This study aimed to compare ILD reporting associations among antineoplastic agents used in these malignancies and to provide external clinical context from the published literature. We analyzed FAERS reports of ILD associated with 65 prespecified antineoplastic agents used in patients with sex hormone-sensitive solid tumors. Each drug\u2019s ILD reporting association was evaluated using disproportionality analysis (reporting odds ratios), multivariable regression, and time-to-onset analyses. In addition, we conducted a structured PubMed search through March 15, 2026 for eligible human case reports and case series involving these agents. Among 8,146 FAERS ILD reports, trastuzumab deruxtecan (T-DXd) showed a prominent ILD signal and the highest adjusted reporting association. Some sex hormone-pathway agents, including darolutamide and fulvestrant, also showed elevated ILD reporting associations, and concomitant SHA analyses identified additional signals. Older age and lower body weight were independently associated with ILD reporting. In exploratory complete-case TTO analyses, death-recorded ILD reports showed a shorter median reported TTO than non\u2013death-recorded ILD reports; in FDR-adjusted body-weight\u2013stratified analyses, this pattern was observed in the \u226570 kg subgroup but not in the &amp;lt;70\u00a0kg subgroup and should be interpreted as hypothesis-generating. The literature review identified 85 eligible publications comprising 98 case-level records and provided supportive clinical context for the FAERS findings. Overall, ILD reporting associations vary across antineoplastic agents used for sex hormone-sensitive solid tumors, even within the same class. Notably, underemphasized signals were observed for certain SHAs. These findings support early ILD monitoring and attention to patient factors such as age and body weight, while underscoring the need for cautious interpretation and confirmation in prospective and real-world studies.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1840323","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T05:21:38Z","timestamp":1781068898000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Antineoplastic agent-associated interstitial lung disease in breast, ovarian, and prostate cancers: a pharmacovigilance study using the FDA adverse event reporting system"],"prefix":"10.3389","volume":"17","author":[{"given":"Keyuan","family":"Du","sequence":"first","affiliation":[{"name":"Department of Breast Surgery, The First Affiliated Hospital of Xi\u2019an Jiaotong University","place":["Xi\u2019an, Shaanxi, China"]},{"name":"The First Clinical School of Medicine, Xi\u2019an Jiaotong University","place":["Xi\u2019an, Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenglong","family":"Duan","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, The First Affiliated Hospital of Xi\u2019an Jiaotong University","place":["Xi\u2019an, Shaanxi, China"]},{"name":"The First Clinical School of Medicine, Xi\u2019an Jiaotong University","place":["Xi\u2019an, Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, The First Affiliated Hospital of Xi\u2019an Jiaotong University","place":["Xi\u2019an, Shaanxi, China"]},{"name":"The First Clinical School of Medicine, Xi\u2019an Jiaotong University","place":["Xi\u2019an, Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianing","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, The First Affiliated Hospital of Xi\u2019an Jiaotong University","place":["Xi\u2019an, Shaanxi, China"]},{"name":"The First Clinical School of Medicine, Xi\u2019an Jiaotong University","place":["Xi\u2019an, Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinsui","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, The First Affiliated Hospital of Xi\u2019an Jiaotong University","place":["Xi\u2019an, Shaanxi, China"]},{"name":"The First Clinical School of Medicine, Xi\u2019an Jiaotong University","place":["Xi\u2019an, Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, The First Affiliated Hospital of Xi\u2019an Jiaotong University","place":["Xi\u2019an, Shaanxi, China"]},{"name":"The First Clinical School of Medicine, Xi\u2019an Jiaotong University","place":["Xi\u2019an, Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihao","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, The First Affiliated Hospital of Xi\u2019an Jiaotong University","place":["Xi\u2019an, Shaanxi, China"]},{"name":"The First Clinical School of Medicine, Xi\u2019an Jiaotong University","place":["Xi\u2019an, Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenrong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, The First Affiliated Hospital of Xi\u2019an Jiaotong University","place":["Xi\u2019an, Shaanxi, China"]},{"name":"The First Clinical School of Medicine, Xi\u2019an Jiaotong University","place":["Xi\u2019an, Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, The First Affiliated Hospital of Xi\u2019an Jiaotong University","place":["Xi\u2019an, Shaanxi, China"]},{"name":"The First Clinical School of Medicine, Xi\u2019an Jiaotong University","place":["Xi\u2019an, Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yibin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, The First Affiliated Hospital of Xi\u2019an Jiaotong University","place":["Xi\u2019an, Shaanxi, China"]},{"name":"The First Clinical School of Medicine, Xi\u2019an Jiaotong University","place":["Xi\u2019an, Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, The First Affiliated Hospital of Xi\u2019an Jiaotong University","place":["Xi\u2019an, Shaanxi, China"]},{"name":"The First Clinical School of Medicine, Xi\u2019an Jiaotong University","place":["Xi\u2019an, Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongxia","family":"Sheng","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, The First Affiliated Hospital of Xi\u2019an Jiaotong University","place":["Xi\u2019an, Shaanxi, China"]},{"name":"The First Clinical School of Medicine, Xi\u2019an Jiaotong University","place":["Xi\u2019an, Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, The First Affiliated Hospital of Xi\u2019an Jiaotong University","place":["Xi\u2019an, Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, The First Affiliated Hospital of Xi\u2019an Jiaotong University","place":["Xi\u2019an, Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizhe","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, The First Affiliated Hospital of Xi\u2019an Jiaotong University","place":["Xi\u2019an, Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1296890","article-title":"Interstitial lung disease: a review of classification, etiology, epidemiology, clinical diagnosis, pharmacological and non-pharmacological treatment","volume":"11","author":"Althobiani","year":"2024","journal-title":"Front Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01052-2","article-title":"Interstitial lung diseases","volume":"400","author":"Wijsenbeek","year":"2022","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.3669","article-title":"Interstitial lung disease: a review","volume":"331","author":"Maher","year":"2024","journal-title":"JAMA"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-022-03932-3","article-title":"Incidence and prognostic factors in severe drug-induced interstitial lung disease caused by antineoplastic drug therapy in the real world","volume":"148","author":"Kaku","year":"2022","journal-title":"J Cancer Res Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100404","article-title":"Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment","volume":"7","author":"Conte","year":"2022","journal-title":"ESMO Open"},{"key":"B6","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s11523-013-0289-2","article-title":"Pulmonary complications with the use of mTOR inhibitors in targeted cancer therapy: a systematic review and meta-analysis","volume":"9","author":"Gartrell","year":"2014","journal-title":"Targ Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s10549-020-05754-8","article-title":"Incidence of pneumonitis\/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer","volume":"183","author":"Hackshaw","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0343","article-title":"Emerging perspectives on mTOR inhibitor-associated pneumonitis in breast cancer","volume":"23","author":"Alvarez","year":"2018","journal-title":"Oncologist"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1001\/jamaoncol.2019.0393","article-title":"Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis","volume":"5","author":"Wang","year":"2019","journal-title":"JAMA Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/srep44173","article-title":"PD-1 inhibitors increase the incidence and risk of pneumonitis in cancer patients in a dose-independent manner: a meta-analysis","volume":"7","author":"Wu","year":"2017","journal-title":"Sci Rep"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2017.04.177","article-title":"Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer","volume":"152","author":"Khunger","year":"2017","journal-title":"Chest"},{"key":"B12","doi-asserted-by":"publisher","first-page":"599","DOI":"10.20892\/j.issn.2095-3941.2020.0102","article-title":"The mechanism and risk factors for immune checkpoint inhibitor pneumonitis in non-small cell lung cancer patients","volume":"17","author":"Zhai","year":"2020","journal-title":"Cancer Biol Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.830631","article-title":"Checkpoint inhibitor pneumonitis induced by anti-PD-1\/PD-L1 therapy in non-small-cell lung cancer: occurrence and mechanism","volume":"13","author":"Yin","year":"2022","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1266850","article-title":"Immune checkpoint inhibitor-related pneumonitis: research advances in prediction and management","volume":"15","author":"Lin","year":"2024","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-01283","article-title":"Pembrolizumab plus docetaxel versus docetaxel for previously treated metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-921 trial","volume":"43","author":"Petrylak","year":"2025","journal-title":"JCO"},{"key":"B16","doi-asserted-by":"publisher","first-page":"323","DOI":"10.21037\/atm-22-5062","article-title":"Organising pneumonia caused by hormone (tamoxifen) therapy after radiotherapy for breast cancer: a case report and review of the literature","volume":"11","author":"Zhong","year":"2023","journal-title":"Ann Transl Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s12282-022-01346-0","article-title":"Interstitial lung disorders following postoperative radiotherapy with concurrent or sequential hormonal therapy for breast cancer: a nationwide database study in Japan","volume":"29","author":"Konishi","year":"2022","journal-title":"Breast Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.101613","article-title":"Incidence of interstitial lung disease and cardiotoxicity with trastuzumab deruxtecan in breast cancer patients: a systematic review and single-arm meta-analysis","volume":"8","author":"Soares","year":"2023","journal-title":"ESMO Open"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100554","article-title":"Pooled analysis of drug-related interstitial lung disease and\/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies","volume":"7","author":"Powell","year":"2022","journal-title":"ESMO Open"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309169","article-title":"Mirvetuximab soravtansine in FR\u03b1-positive, platinum-resistant ovarian cancer","volume":"389","author":"Moore","year":"2023","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-0991","article-title":"FDA approval summary: mirvetuximab soravtansine-gynx for FR\u03b1-positive, platinum-resistant ovarian cancer","volume":"29","author":"Dilawari","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B22","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/s42003-022-03554-y","article-title":"Considering hormone-sensitive cancers as a single disease in the UK biobank reveals shared aetiology","volume":"5","author":"Ahmed","year":"2022","journal-title":"Commun Biol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"Van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiology Drug"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15336","article-title":"Analysis of adverse event of interstitial lung disease in men with prostate cancer receiving hormone therapy using the Food and Drug Administration Adverse Event Reporting System","volume":"89","author":"Wu","year":"2023","journal-title":"Brit J Clin Pharma"},{"key":"B25","volume-title":"Flutamid Stada 250 Mg Tablet: Summary of Product Characteristics","year":"2020"},{"key":"B26","volume-title":"Casodex (Bicalutamide) Tablets, for Oral Use [Prescribing Information]","year":"2017"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10263","article-title":"Severe interstitial pneumonitis associated with docetaxel administration","volume":"94","author":"Read","year":"2002","journal-title":"Cancer"},{"key":"B28","article-title":"A case of recurrent breast cancer with drug-induced interstitial pneumonia triggered by the switch from an original to a generic aromatase inhibitor","volume":"47","author":"Hirohashi","year":"2020","journal-title":"Gan To Kagaku Ryoho"},{"key":"B29","article-title":"A case of interstitial pneumonitis induced by palbociclib","volume":"47","author":"Okura","year":"2020","journal-title":"Gan To Kagaku Ryoho"},{"key":"B30","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1093\/oncolo\/oyac205","article-title":"Palbociclib with fulvestrant or letrozole in endocrine-sensitive patients with HR-positive\/HER2-negative advanced breast cancer: a detailed safety analysis of the randomized PARSIFAL trial","volume":"28","author":"Di Cosimo","year":"2023","journal-title":"Oncologist"},{"key":"B31","volume-title":"Enhertu (Fam-Trastuzumab Deruxtecan-Nxki) [Prescribing Information]","year":"2025"},{"key":"B32","volume-title":"Elahere (Mirvetuximab Soravtansine-Gynx) Injection [Prescribing Information]","year":"2024"},{"key":"B33","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1164\/rccm.200911-1720OC","article-title":"Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma","volume":"182","author":"White","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.ygyno.2021.05.012","article-title":"Risk of pneumonitis in cancer patients treated with PARP inhibitors: a meta-analysis of randomized controlled trials and a pharmacovigilance study of the FAERS database","volume":"162","author":"Ma","year":"2021","journal-title":"Gynecologic Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.68.2005","article-title":"Pneumonitis in patients treated with anti\u2013programmed death-1\/programmed death ligand 1 therapy","volume":"35","author":"Naidoo","year":"2017","journal-title":"JCO"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1179\/1973947815Y.0000000029","article-title":"Paclitaxel-induced pneumonitis in patients with breast cancer: case series and review of the literature","volume":"29","author":"Bielopolski","year":"2017","journal-title":"J Chemother"},{"key":"B37","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s40779-024-00526-7","article-title":"The implications of single-cell RNA-seq analysis in prostate cancer: unraveling tumor heterogeneity, therapeutic implications and pathways towards personalized therapy","volume":"11","author":"Feng","year":"2024","journal-title":"Military Med Res"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.34133\/research.1128","article-title":"Intratumoral androgens and genetic variants driving therapy resistance in prostate cancer","volume":"9","author":"Ye","year":"2026","journal-title":"Research"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpha.2025.101232","article-title":"Novel hormone therapies for advanced prostate cancer: understanding and countering drug resistance","volume":"15","author":"Wang","year":"2025","journal-title":"J Pharm Anal"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1840323\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T05:21:41Z","timestamp":1781068901000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1840323\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":39,"alternative-id":["10.3389\/fimmu.2026.1840323"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1840323","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]},"article-number":"1840323"}}